A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Inclusion Criteria:
Exclusion Criteria:
Winston-Salem, North Carolina 27103, United States
Ciudad Automoma Buenos Aires, C1120AAT, Argentina
Córdoba, 5000, Argentina
Jardim Blumenau, 89010 340, Brazil
Porto Alegre, 90610-000, Brazil
São José do Rio Preto, 15090-000, Brazil
São Paulo, 01246 000, Brazil
Beijing, 100021, China
Changsha Shi, 410013, China
Plzen-Bory, 305 99, Czechia
Düesseldorf, 40225, Germany
Kawagoe-Shi, 350-8550, Japan
Kisarazu-shi, 292-8535, Japan
Sochi, 354057, Russia
Gangnam Gu, 06351, South Korea
Hwasun-gun, 58128, South Korea
Ankara, 06050, Turkey (Türkiye)
Istanbul, 34732, Turkey (Türkiye)